Orginal Publication Date
MCV/Q, Medical College of Virginia Quarterly
In its brief lifetime as a known peptide, somatostatin has provided a truly remarkable story filled with surprising developments from unexpected quarters. The foundation was set in 1969, when Krulich and McCann reported that fractions of a crude hypothalamic extract inhibited the secretion of growth hormone. In 1973, Guillemin's laboratory reported the sequence and synthesis of a fourteen amino acid peptide with the same inhibitory effect. It occurs in both a cyclic and linear form, each displaying equal biological activity. Somatostatin was assigned as its name, but it is also commonly referred to as growth hormone release inhibitory factor (GHRIF) or somatotropin-release inhibiting factor (SRIF).
© VCU. Licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License. http://creativecommons.org/licenses/by-nc-sa/3.0 Acknowledgement of the Virginia Commonwealth University Libraries as a source is required.
Is Part Of
VCU University Archives